Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Mangoceuticals, Inc. Common Stock (MGRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: MGRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 7.96% | Avg. Invested days 49 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 18.41M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.76 | 52 Weeks Range 1.32 - 7.05 | Updated Date 06/29/2025 |
52 Weeks Range 1.32 - 7.05 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.63 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -3141.81% |
Management Effectiveness
Return on Assets (TTM) -53.56% | Return on Equity (TTM) -115.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 18386227 | Price to Sales(TTM) 36.03 |
Enterprise Value 18386227 | Price to Sales(TTM) 36.03 | ||
Enterprise Value to Revenue 35.98 | Enterprise Value to EBITDA -0.51 | Shares Outstanding 10644500 | Shares Floating 8117841 |
Shares Outstanding 10644500 | Shares Floating 8117841 | ||
Percent Insiders 27.82 | Percent Institutions 0.66 |
Upturn AI SWOT
Mangoceuticals, Inc. Common Stock
Company Overview
History and Background
Mangoceuticals, Inc. was formed to develop and market erectile dysfunction (ED) products and services. It focuses on telemedicine and direct-to-consumer sales. The company's history is relatively short, beginning its operations in recent years.
Core Business Areas
- Telemedicine Platform: Mangoceuticals provides a telemedicine platform for men to access ED treatments remotely, including consultations and prescriptions.
- Direct-to-Consumer Sales: The company markets and sells its ED products directly to consumers through its online platform, focusing on convenience and discretion.
Leadership and Structure
The leadership team consists of individuals focused on pharmaceutical marketing and telemedicine. The organizational structure is typical of a small, publicly traded company, with functional departments like marketing, sales, and operations.
Top Products and Market Share
Key Offerings
- Mango Rx: Mango Rx is an on-demand erectile dysfunction (ED) drug delivered discreetly to the consumer after an online doctor's visit and prescription. Market share data is not publicly available due to the competitive landscape. Competitors include Viagra (Pfizer), Cialis (Eli Lilly), and generic ED medications.
Market Dynamics
Industry Overview
The erectile dysfunction market is substantial and growing, driven by an aging population and increasing awareness. The market includes both prescription medications and over-the-counter alternatives.
Positioning
Mangoceuticals aims to differentiate itself through its direct-to-consumer approach, focusing on convenience and accessibility. Its competitive advantage lies in its telemedicine platform and branding.
Total Addressable Market (TAM)
The global erectile dysfunction market is estimated to be in the billions of dollars. Mangoceuticals is positioned to capture a segment of this market through its online platform and targeted marketing efforts.
Upturn SWOT Analysis
Strengths
- Direct-to-consumer model
- Telemedicine platform
- Focus on a specific niche market
- Discreet and convenient access to ED treatments
Weaknesses
- Limited operating history
- Reliance on a single product
- High marketing expenses
- Limited brand recognition compared to established pharmaceutical companies
Opportunities
- Expanding product offerings to include other men's health products
- Increasing market penetration through strategic partnerships
- Leveraging telemedicine platform for other health conditions
- Geographic expansion
Threats
- Competition from established pharmaceutical companies
- Regulatory changes affecting telemedicine and online pharmacies
- Patent expirations for ED drugs leading to generic competition
- Negative publicity or safety concerns related to ED treatments
Competitors and Market Share
Key Competitors
- PFE
- LLY
- VRX
Competitive Landscape
Mangoceuticals faces intense competition from established pharmaceutical companies with significantly larger resources and brand recognition. Its competitive advantage lies in its direct-to-consumer approach and telemedicine platform, but it must overcome challenges related to marketing expenses and brand building.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the company's relatively short operating history.
Future Projections: Future growth projections are not readily available from analyst estimates.
Recent Initiatives: Recent initiatives include marketing campaigns to increase brand awareness and user acquisition efforts to grow the telemedicine platform user base.
Summary
Mangoceuticals is a nascent company in the ED market leveraging a direct-to-consumer telemedicine approach. It faces strong competition from established pharmaceutical giants. Its success hinges on effective marketing, user acquisition, and potential expansion into related men's health products. It needs to be aware of regulatory issues around telemedicine.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- Company website
- Industry reports
- SEC filings
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise. Financial performance data is limited due to the company's short operating history.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mangoceuticals, Inc. Common Stock
Exchange NASDAQ | Headquaters Dallas, TX, United States | ||
IPO Launch date 2023-03-21 | Co-Founder, CEO & Chairman Mr. Jacob D. Cohen | ||
Sector Healthcare | Industry Health Information Services | Full time employees 3 | Website https://www.mangoceuticals.com |
Full time employees 3 | Website https://www.mangoceuticals.com | ||
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. The company markets and sells its products online through its website www.MangoRX.com. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.